Feeds
Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.
Merck & Co. is set to complete its $41 billion acquisition of Schering-Plough Corp. later Tuesday, creating the world's second-largest drugmaker, behind Pfizer Inc.
The European Union on Friday approved the proposed tie-up of U.S. drug makers Merck & Co. and Schering-Plough Corp. which would create the second-biggest global producer of prescription medicines.
Drugmaker Schering-Plough Corp. on Thursday ported lower revenue and a smaller profit in the third quarter, partly due to slightly higher spending on taxes and research.
Drugmaker Merck & Co. filed papers with regulators in the European Union seeking approval of its planned acquisition of Schering-Plough Corp.
Drugmaker Schering-Plough Corp. has been denied a $473 million tax refund by a federal judge who ruled the company made two transactions just to avoid paying taxes on $690 million in profits from overseas subsidiaries.
A federal court in Newark, N.J. has rejected Schering-Plough Corp.'s request for a $473 million tax refund related to the drugmaker's efforts to avoid paying taxes on $690 million in overseas profits it brought back to the U.S. from offshore subsidiaries.
Richard T. Clark, current president and CEO of Merck, said Monday the company will restructure into five divisions after it completes its buyout of rival Schering-Plough for $41.1 billion.
Schering-Plough Corp.'s new drug for schizophrenia and bipolar disorder, Saphris, has been approved by the Food and Drug Administration.
Shareholders of drugmakers Merck & Co. and Schering-Plough Corp. on Friday both overwhelmingly backed a huge tie-up of the New Jersey neighbors, and shares of both companies jumped.
Merck & Co. and Schering-Plough Corp. said Wednesday they will pay $41.5 million to settle lawsuits claiming the drugmakers, partners on two blockbuster cholesterol drugs, delayed unfavorable study results because they would hurt sales.
Federal health regulators said Tuesday an experimental psychiatric drug from Schering-Plough Corp. appears to be a safe and effective treatment for patients with schizophrenia and bipolar disorder.
Drugmaker Schering-Plough Corp. on Tuesday reported reduced second-quarter sales mainly due to the strong dollar, but its profit still jumped 49 percent, thanks to much lower one-time charges than a year ago. Its shares rose 3 percent.
Merck & Co. and Schering-Plough Corp. will hold special meetings in August for their stockholders to approve their pending merger, which would make the combined company the world's second-largest prescription drugmaker.
Drugmaker Merck & Co. is considering selling some of its veterinary medicine assets or the animal health business of Schering-Plough Corp., as it prepares to acquire its New Jersey neighbor.
The battle over billions in sales from Johnson & Johnson's top drug is heating up, with the health products maker demanding arbitration to end its revenue-sharing deal with Schering-Plough Corp., due to its merger with rival drugmaker Merck & Co.
A suspicious surge in trading of Schering-Plough Corp. shares just before news of its merger deal with fellow drugmaker Merck & Co. is being investigated by federal regulators, according to a published report.
Schering-Plough Corp. Chief Executive Fred Hassan's compensation slipped 34 percent in 2008, mainly due to a decline in stock-based awards as the company's share price fell, according to an Associated Press analysis of data filed with regulators Monday.
Schering-Plough Corp., in the process of being acquired by competitor Merck & Co., said Tuesday drug sales fell in the first quarter but profit tripled because of cost cutting and a charge in last year's quarter related to an acquisition.
Fears over shaky credit markets are baked into Merck & Co. Inc.'s $41.1 billion agreement to buy rival drugmaker Schering-Plough Corp., with the cost for a breakup of the deal is much higher if Merck's financing doesn't come through.
Drugmaker Schering-Plough Corp. posted a fourth-quarter profit that topped estimates as lingering buyout charges for Organon Biosciences NV decreased, but revenue suffered from a stronger U.S. dollar and lagging cholesterol drug sales.
The first high-tech, long-acting treatment for hepatitis C in children, a two-drug combination from Schering-Plough Corp., has been approved by the Food and Drug Administration.
Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday.
Higher expenses and charges pulled down Schering-Plough Corp.'s third-quarter profit by 23 percent, the drug developer said Tuesday, but a series of restructuring and expansion moves helped it top Wall Street forecasts.
Log In | Register
